Komen Central and South Jersey Announced Karen M. Correa, MS, PhD, CCRA to Board of Directors

Komen NJ, PA, WV and DE
2 min readMay 3, 2018

--

Karen M. Correa, MS, PhD, CCRA

Susan G. Komen Central and South Jersey (Komen CSNJ) announced the appointment of Karen M. Correa, MS, PhD, CCRA of Adare Pharmaceuticals to the board of directors as its mission chair, leading the Affiliate’s mission priorities and initiatives.

“We are thrilled to have Karen Correa as part of the Komen CSNJ board of directors,” said Suzanne Corson, executive director of Komen CSNJ. “Her drive to break down barriers that prevent targeted populations from receiving the breast cancer care they need will further our vision of a world without breast cancer.”

Correa is an industry veteran with 26 years of experience in clinical trials, and a focus on recruiting specialized populations. She received her PhD in health services from Trident University International, and has since championed the representation of targeted communities in clinical trials and the medical treatment fields.

“As a board member of Komen CSNJ, I am committed to engaging with the community via educational and awareness campaigns to achieve our goals of eradicating breast cancer in our community,” said Correa. “Through this role, I am able to foster change and continue to fulfil my purpose of serving others in a life-altering condition.”

Working with other pharmaceutical and biotech companies, as well as patient advocacy and investigative sites, Correa supports the ongoing need for clinical trial awareness and inclusion of diverse populations. She spearheads initiatives to increase awareness and access to clinical trials in all communities, particularly within those that may experience barriers to participating in clinical trials.

“I have been afforded the knowledge and understanding of the importance that diversity in clinical trials has on patient treatment and success,” said Correa. “I recognize the need for a more diverse representation of patients to ensure that the novel treatments being approved are safe and effective among all populations.”

Correa will be instrumental in her role as the board’s mission chair to support localized priorities that focus on breaking down barriers to breast cancer care through patient navigation, breast cancer education, access to care and free mammograms.

“Barriers are overcome with action that includes ongoing attention to awareness, education and access,” said Correa. “I am now a passionate, dedicated and committed resource to participate and drive these activities for the central and southern New Jersey region.”

Susan G. Komen Central and South Jersey (Komen CSNJ) is working to better the lives of those facing breast cancer in the local community. Through events like the Komen CSNJ Race for the Cure®, Komen CSNJ has invested nearly $15 million in community breast health programs in its 13-county service area and has helped contribute to the more than $920 million invested globally in research. For more information, call 609–896–1201 or visit komencsnj.org.

--

--

Komen NJ, PA, WV and DE
Komen NJ, PA, WV and DE

Written by Komen NJ, PA, WV and DE

Our mission is to save lives by meeting the most critical needs in our communities and investing in breakthrough research to prevent & cure breast cancer.

No responses yet